In what “appears to be a first for a major drug company,” GlaxoSmithKline “will no longer pay doctors to promote its products and will stop tying compensation of sales representatives to the number of prescriptions doctors.” A spokesman says the practices involve “tens of millions” of dollars. “We keep asking ourselves, are there different ways, more effective ways of operating than perhaps the ways we as an industry have been operating over the last 30, 40 years?” CEO Andrew Witty tells Katie Thomas.